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Patency of percutaneous transluminal renal angioplasty: A prospective
sonographic study. Evaluation of percutaneous transluminal renal angio-
plasty (PTRA) is today based primarily on clinical criteria rather than
direct investigation of luminal width. In this study, we examined renal
blood flow by color-coded duplex sonography (CCD) in order to correlate
blood pressure as well as renal function with the true renovascular
patency. Fifty consecutive patients suspected of suffering from renovascu-
lar disease and treated by PTRA were included for a prospective
sonographic study. In all PTRA was performed on 63 renal arteries.
Thirty-seven patients were diagnosed to have atherosclerosis and 13
patients to have fibromuscular dysplasia (FMD). Examinations were
performed using CCD before PTRA, and one day, three months, six
months and 12 months after PTRA. If CCD showed a restenosis  60%,
CCD was non-conclusive or hypertension deteriorated, angiography and,
if necessary, catheter re-intervention were performed. The primary pa-
tency rate after 12 months was 73%, and could be improved to 94% overall
when treated restenoses (N = 22) were included. Restenosis was more
frequent in patients with mild residual stenosis identified by CCD one day
after PTRA (P = 0.002). There was neither a significant difference in the
restenosis rate in patients with atherosclerosis versus FMD, nor in patients
with ostial versus non-ostial lesions. Hypertension was improved or cured
in 70% of patients with atherosclerosis, and in 85% of those with FMD.
Nevertheless, hypertension deteriorated in 12% of the patients without
restenosis, and no deterioration was present in 14% of the patients with
restenosis. A decrease in serum creatinine levels by more than 15% was
observed in 12 of 22 patients with impaired renal function and patent renal
artery during follow-up. These results suggest that optimal therapeutic
efficiency can be obtained using PTRA followed by systematic CCD.
Renovascular disease is frequently associated with hypertension
and deteriorating renal function [1, 2]. Treatment of renal artery
stenosis has recently changed from merely reducing blood pres-
sure to maintaining and restoring renal function as well. Renal
artery stenosis resulting from atherosclerosis shows a progressive
course, with 10 to 17% of the lesions occluding within two to five
years. With increased longevity and new effective antihypertensive
medication, the prevalence of vascular lesions affecting renal
viability is increasing, possibly accounting for up to 15% of
end-stage renal disease [3—5]. Percutaneous transluminal renal
angioplasty (PTRA) has been established as an efficient method
for treatment of renal artery stenosis associated with renovascular
hypertension or ischemic nephropathy [6—9]. Most studies dealing
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with endovascular or surgical treatment of renal artery stenosis
lack prospective angiographic or sonographic follow-up of treated
vessels, and long-term results are often based solely on blood
pressure measurements [10—12]. However, recurrence of arterial
hypertension cannot be attributed to recurrence of renal artery
stenosis with certainty, because hypertension is not a sensitive
indicator of this process [13, 14]. Color-coded duplex sonography
(CCD) has been shown to represent a• reliable method for
non-invasive assessment of renal artery stenoses [15, 16].
The aim of this prospective study was to perform a systematic
investigation of the results of PTRA with regard to the patency
rate, and to correlate sonographic and/or angiographic patency of
treated renal arteries with the effects on blood pressure and renal
function.
Methods
Subjects
Fifty patients who met the inclusion criteria of successful PTRA
and regular, prospectively planned follow-up were selected from a
total of 56 consecutive patients with attempted PTRA between
January 1994 and July 1995. Three patients with four renal artery
stenoses were excluded because of failed initial PTRA. Two
patients were lost from follow-up, and one additional patient died
from cardiac failure two months after catheter intervention.
Complications associated with PTRA included one case of pen-
renal bleeding treated conservatively and one false aneurysm at
the puncture site treated by sonographically directed compres-
sion.
The reported series included 26 women and 24 men with a
mean age of 60 11 SD (range 33 to 78) years. At the time of
inclusion, 47 patients had 59 renal artery lesions (58 stenoses,
range 60 to 99%, one atherosclerotic occlusion) not previously
treated and three patients had a restenosis after angioplasty of
four renal arteries. (For simplification the atherosclerotic renal
artery occlusion included in the series will be summarized under
the term stenosis). Demographic data of the study population arc
given in Table 1. Indication for PTRA was suspected renovascular
hypertension in all patients, and in addition an impaired renal
function (serum creatinine concentration  110 imol/liter) in 25
patients. Renal artery obstruction was due to atherosclerosis in 37
patients and to FMD in 13 patients. FMD was confirmed by its
arteriographic appearance, absent atherosclerotic changes of the
aorta, and age of the patient [171. During an average follow-up of
13 3 (median 12, range 6 to 21) months, 12 restenoses and six
recurrent or second restenoses (re-restenoses) occurred of the 63
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Table 1. Demographic data of the 50 patients according to the etiology
of renal artery stenosis or occlusion
Fibromuscular
Characteristic
Atherosclerosis
(N = 37)
dysplasia(N = 13)
Age±sDyearsa 63±8 49±9
Creatinine SD jiniol/ 155 81 87 25
liter"
Women/Men N1' 14/23 12/1
Hypertension N 37 13
Hypercholesterolemia Nc,I 20 1
Smoking history N 18 3
Diabetes mellitus N 7 1
Comparison between renal artery obstructions due to atherosclerosis
and fibromuscular dysplasia: ap < 0.001, bp = 0.001, "P = 0.045d Cholesterol > 5.2 mmol/liter or cholesterol/FIDL cholesterol ratio >5
renal arteries included in the series and were treated by repeated
PTRA. Altogether a total of 81 PTRAs, 59 primary (58 stenoses,
one occlusion) and 22 secondary (4 post-angioplasty restenoses
initially included in the series, 12 restenoses, 6 re-restenoses) were
performed. PTRA was performed unilaterally in 53 and bilaterally
in 14 cases. Palmaz-Schatz stents were inserted into eight renal
arteries because of inadequate primary result or restenosis after
PTRA.
Diagnostic work-up
Baseline diagnostic work-up for renal artery stenosis was based
on intraarterial digital subtraction angiography. CCD was applied
if the functional significance of a stenosis was difficult to deter-
mine angiographically (Table 2). A renal artery stenosis with
 60% diameter reduction assessed by angiography, CCD or both
was defined significant. Baseline and follow-up examinations
included recording of daily consumption of antihypertensive
drugs, blood pressure and serum creatinine concentration. Fol-
low-up examinations were performed one day, and three, six and
12 months after PTRA, and included CCD studies of the renal
arteries in all patients. Intraarterial angiography was added in
case of a non-conclusive CCD study or a renal artery restenosis 
60% at CCD. To avoid falsely negative sonographic studies,
patients with less than 60% renal artery restenosis at CCD but
recurrent or deteriorating arterial hypertension underwent an-
giography. The sonographer was not aware of the angiographic
results. Primary patency rate, calculated by the life table method
was defined as patency rate after the first PTRA (N = 59),
whereas secondary patency rate included results after all further
PTRAs performed to treat restenoses (N = 81).
CCD studies were performed by using commercially available
high resolution ultrasound equipment (Acuson 1281XP10, Moun-
tain View, CA, USA) using a 2.5-, 3.5- or 4.0-MHz sector array
transducer. Direct examination was used to evaluate the aorta and
renal arteries at the site of intervention [15, 18, 19]. Intrastenotic
peak systolic velocity (PSV) greater than 180 cm/second corrected
for the angle of insonation and a renal-to-aortic flow velocity ratio
(RAR) greater than 3.5 was considered indicative of  60% renal
artery stenosis. PSV over 180 cm/second with a RAR less than 3.5
and normal indirect Doppler criteria within segmental renal
arteries were used to indicate a residual stenosis less than 60%.
Indirect Doppler criteria were used to exclude a renal artery
stenosis  60% based on an acceleration time less than 70
Table 2. Baseline renal artery findings at intra-arterial angiography
prior to percutaneous transluminal renal angioplasty in 50 patients with
59 renal artery stenosis or occlusions not previously treated and 22
post-angioplasty restenoses
Characteristics Vessels N
Diameter reduction
60—79% 30
80—99% 46
100% 1
Not applicablea 4
Localization of obstruction
Ostium (juxta-aortic) 15
Proximal 50
Multifocal/distal 16
"Fibromuscular dysplasia with significant stenosis ( 60%) verified at
color-coded duplex sonography before endovascular intervention
msecond and a preserved early systolic deceleration [16, 20]. A
renal artery was considered free of residual stenosis if both the
PSV measured less than 180 cm/second and the RAR less than
3.5.
The patient was considered free from hypertension if diastolic
blood pressure was less than 90 mm Hg, and systolic blood
pressure was less than 140 mm Hg without antihypertensive
medication. Hypertension was considered improved if there was a
systolic or diastolic pressure reduction of more than 20 mm Hg, or
reduced medication was required to achieve normotensive blood
pressure values. Renal function was considered improved if the
serum creatinine concentration was reduced by more than 15%
below the preinterventional level, unchanged if serum creatinine
concentration was 15% of the preinterventional level, and
impaired if the serum creatinine concentration was more than
15% above the preinterventional level.
Data analysis
Numerical data were expressed as mean SD. Median and
range are presented in Table 5 because of skewed distributions.
Statistical significance was evaluated by using non-parametric
tests, the Mann-Whitney U-test for comparison between groups
and the Wilcoxon test for comparison within groups. Contingency
table analysis (Fisher's exact test) was used to analyze differences
within groups of patients. Two tailed P values below 0.05 were
considered to indicate significance. Patency rates were calculated
by the life-table method.
Results
A total of 152 out of 168 CCD follow-up investigations after
PTRA were estimated to be conclusive (90%). The average length
of time for complete renal CCD examination was 38 14 (range
20 to 75, median 35) minutes. Non-conclusive CCD studies
resulted from obesity or excessive accumulation of gas in the
intestine. Seventy-five of 81 treated renal arteries (93%) could be
assessed by CCD alone, and six (7%) required intraarterial
angiography. According to the study protocol, a subgroup of 25
treated renal arteries with adequate CCD examination were
additionally evaluated by intra-arterial angiography. This sub-
group included 19 post-angioplasty restenoses ( 60% at CCD)
and six renal arteries in six patients with recurrent or deteriorating
arterial hypertension despite exclusion of a restenosis at CCD.
Furthermore, four renal arteries were studied by intra-arterial
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63 61 59 51
59 59 48 43
angiography simultaneously with evaluation of the coronary ar-
teries. Comparing the results from angiogram and CCD to
discriminate  60% restenosis there were 19 true-positive, eight
true-negative, two false-positive and no false-negative sono-
graphic findings [sensitivity 100%, specificity 80%, overall accu-
racy 93% (95% CI 84 to 100%)].
Patency
Sixteen of the 59 renal arteries treated by PTRA for the first
time developed a restenosis  60% during follow-up (mean 11
3, median 12 months). After secondary catheter intervention of
restenosis (N = 22) only three of 63 renal arteries remained with
restenosis and/or reocclusion at the end of follow-up (mean 8 5,
median 9 months). The patency rate at 12 months, calculated by
the life-table method, was 73% after primary PTRA, and in-
creased to 94% when secondary PTRAs of restenoses were
included (Fig. 1). The only patient with an atherosclerotic occlu-
sion of a renal artery showed reocclusion after three consecutive
PTRAs and was subsequently treated with an anti-hypertensive
medication. Two secondary PTRAs for in-stent restenoses also
failed but these patients were successfully treated by an aorto-
renal bypass operation (Fig. 2). Seven percent of all attempted
PTRAs failed, four due to initial technical failures were not
included in the follow-up series, and two due to technical failures
of secondary PTRAs with a successful aorto-renal bypass opera-
tion during follow-up.
Restenoses were more frequently seen in renal arteries pre-
sented with mild residual stenosis less than 60% (PSV > 180
cm/second, RAR < 3.5) compared to those without residual
stenosis (PSV < 180 cm/second, RAR < 3.5) as determined by
CCD one day after PTRA (P =0.002). There was no difference in
the rate of restenosis between patients with renal artery stenosis
due to atherosclerosis compared to those with FMD (Table 3).
Similarly, patients treated for renovascular hypertension associ-
ated with impaired renal function showed no significant difference
in restenoses compared to those treated for renovascular hyper-
tension with normal renal function. The 15 ostial stenoses in-
cluded in the series showed the same rate of restenosis as
non-ostial stenoses treated by angioplasty, with 27% recurrence in
both groups.
Blood pressure
Daily antihypertensive medication was reduced from an aver-
age of 2.3 1.1 to 1.5 0.9 drugs per patient at three months
(P < 0.001), and had to be increased to 1.8 1.2 drugs at 12
months of follow-up (NS). Systolic blood pressure improved from
186 30 mm Hg to 161 28 mm Hg at three months and 149
17 mm Hg at 12 months (P < 0.001 for both). Diastolic blood
pressure decreased from 104 16 mm Hg to 90 14 mm Hg at
three months and 86 11 mm Hg at 12 months (P < 0.001 for
both). Systolic and diastolic blood pressure improvement between
three months and 12 months correlated with the increase in
antihypertensive medication. After primary PTRA, hypertension
was improved or cured in 57% of patients. This rate increased to
74% overall at the end of the follow-up (Table 4). An increase in
blood pressure was observed in 12% of patients despite the
exclusion of a  60% restenosis at CCD and intra-arterial
angiography. However, 14% of patients with restenosis verified at
CCD and intra-arterial angiography showed no increase in blood
pressure.
Renal function
Serum creatinine concentration showed a nonsignificant ten-
dency to decrease after PTRA in the study group (N = 50) as well
as in the subgroup of patients with impaired renal function (N =
25). However, exclusive analysis of those 47 patients with a patent
renal artery after primary and/or secondary PTRA showed a
significant decrease of the serum creatinine concentration in those
patients with impaired renal function (Table 5). Subgroup analysis
of patients with impaired renal function who had recurrent
stenosis and repeated catheter interventions showed no significant
difference from patients with impaired renal function who did not
require a second PTRA. Out of the 25 patients with impaired
renal function, 12 improved, nine were unchanged, and four had
a decrease in renal function during the course of the study. With
deteriorating renal function, the renal artery was patent in one
patient and showed a reocclusion with reduction of kidney size to
less than 8 cm in another patient 12 months after PTRA. These
two patients with failed secondary PTRA of an in-stent restenosis
were successfully treated by an elective aorto-renal bypass oper-
ation. No patient became dependent on dialysis. Renal function
did not decline in any subgroup of patients with normal renal
function before PTRA. There were merely two patients with an
increase of serum creatinine concentration less than 10% of the
values before intervention.
Discussion
This prospective clinical study shows that 73% of renal arteries
were patent 12 months after primary PTRA. With consistent
sonographic follow-up and catheter reintervention in the case of
restenosis, the 12 month patency rate could be increased to 94%
overall. Our strategy of secondary PTRA at recurrence yielded
results equivalent to the 83 to 96% patency rates reported after
surgical revascularization of renovascular disease [21—25]. More-
over, the low complication rate in the present PTRA investigation
indicates a favorable benefit/risk ratio on a short-term basis
compared to surgical series with reported complication and
mortality rates ranging from 8 to 20% and 2 to 6%, respectively
[26, 27]. In addition, it is noteworthy that surgical repair could still
be performed in patients with failed secondary PTRA in this
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Table 3. Comparison of renal post-angioplasty restenosis in
atherosclerosis and fibromuscular dysplasia
Secondary PTRA
Re-
Etiology of renal artery Primary PTRAC Restenosis restenosisc
lesion N N P N P
Atherosclerosis 44 12 4
NSCI NSd
Fibromuscular dysplasia 15 4 2
Unilateral (N = 35), bilateral (N = 24)bUnilateral (N = 12), bilateral (N = 4)
C Unilateral (N = 6)
Comparison between atherosclerosis and fibromuscular dysplasia
series. Successful surgical renal artery reconstruction after PTRA
has been reported by McCann as well [28}. However, a compari-
son of surgical revascularization and PTRA is difficult because of
differences in patient selection and technique, and because many
of these analyses are uncontrolled or retrospective.
In the present study a positive predictor for recurrence was a
Fig. 2. Sequence of events in 50 patients of this
series.
Table 4. Arterial hypertension in the 50 patients with renal artery
stenosis or occlusion after percutaneous transluminal renal angioplasty
(PTRA) at the end of follow-up
Primary PTRAC Secondary PTRA
Hypertension
Atherosclerosis
(N 35)
Fibromuscular
dysplasia(N = 12)
Atherosclerosis(N 37)
Fibromuscular
dysplasia(N = 13)
Cured % 8.6 8.3 10.8 30.8
Improved % 45.7 58.3 59.5 53.8
Unchanged % 45.7 33.3 29.7 15.4
C Not including the three patients with a recurrent renal artery stenosis
after former PTRA
mild residual renal artery stenosis less than 60% at CCD one day
after PTRA. The prevalence of restenosis was similar in renal
artery lesions due to atherosclerosis compared to FMD, despite
more frequent vascular risk factors in the former group. These
findings are compatible with the well-known concept that myointi-
mal hyperplasia and vascular remodeling are the main causes of
restenosis after endovascular interventions independent of the
etiology. An unexpected result of this study was the finding that
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Table 5. Serum creatinine concentration before, and one day, three
months and 12 months after percutaneous transluminal renal
angioplasty (PTRA) in 22 patients with impaired renal function and
documented patent renal artery at the end of follow-up
Creatinine pmol/liter
Patientsmedian
mean sn (range) N P
Before PTRA 169 65 139 (111—319) 22
After PTRA
I day 165 66 138 (106—320) 22 NS
3 months 142 59 119 (83—338) 22 0.003
12 months 134 38 115 (98—223) 19 0.025
a Compared to serum creatinine concentration before PTRA
ostial stenosis and non-ostial stenosis showed an identical recur-
rence rate. Although our study is too small to draw major
conclusions, these results are in accordance with Canzanello et al
and underline the considerable importance of residual stenosis as
a positive predictor for restenosis [29].
Blood pressure was found not to be a sensitive indicator for the
presence of restenosis after PTRA, since 12% of patients with
recurrent arterial hypertension had no significant restenosis, and
14% of patients with restenosis had no recurrent increase of their
blood pressure values as shown by others [13]. Hypertension was
improved or cured in 57% of patients after primary PTRA. This
proportion increased to 74% with secondary PTRAs, and in-
cluded 70% of patients with renal artery stenosis due to athero-
sclerosis and 85% of patients with FMD. This higher response
rate in patients with FMD was already reported by Mahler et al in
the early eighties and could be replicated by others [6, 8, 30].
A decrease in the serum creatinine concentration by more than
15% from the values before PTRA was seen in 12 of 25 patients
with impaired renal function. These results are more favorable
than the natural history of renal artery stenoses with end-stage
renal disease, possibly accounting for up to 15% of cases [3—5].
Although deterioration of renal function was present in four of
our patients, none became dependent on dialysis and in two of
them with failed secondary PTRA, an aorto-renal bypass opera-
tion preserved renal function. These results are comparable with
the literature, however, previous studies were based on clinical
outcome data without correlation to true patency of the renal
arteries [31, 32].
It has been adequately shown that CCD is accurate for detec-
tion of renal artery stenosis and estimation of the degree of
narrowing [16, 18]. This may be important immediately after
reconstruction procedures, and for follow-up examinations. Since
the vessel may appear irregular on post-PTRA angiograms, the
degree of residual stenosis may be difficult to estimate from
angiographic images. Sonographic examination immediately after
endovascular intervention gives an early feedback on the success
of the procedure and is essential if the patient did not have a
beneficial blood pressure response after the interventional proce-
dure. CCD should also be repeated if blood pressure does not
improve or worsens after the typical initial beneficial response
[33]. Thus, early CCD scanning allows interpretation of early
results and facilitates therapeutic decision making. During fol-
low-up CCD may detect restenosis occurring in a considerable
portion of patients after PTRA that can be treated by repeated
catheter intervention. However, a limitation of CCD is the
restricted quality of sonographic assessment in those patients with
excessive obesity or accumulation of gas in the intestine that
prevented conclusive diagnosis in 6 of 81 treated renal arteries
(7%) in this series. Another shortcoming of CCD is that its
reliability depends on the knowledge, skill and experience of the
sonographer. Technical problems involved in performing CCD
interrogation of the renal arteries include inaccurate velocities
due to inappropriate angle-correction, decreased signal-to-noise
ratio with increasing depth of examination and alisasing in high
grade renal artery stenosis. Finally, it is evident that in unselected
patients the rate of correct sonographic evaluation of renal
arteries may decline.
Patients described in this series may be different from those in
surgical studies, since there were no aortic aneurysms and only a
single atherosclerotic renal artery occlusion included for which
surgery may be more adequate either as a primary or as a
secondary procedure. However, the results of this prospective
clinical series with consistent sonographic follow-up and catheter
reintervention in the case of restenosis represent a successful
therapeutic strategy in isolated renal artery stenosis.
Reprint requests to fris Baumgartoer, M.D., Department of Medicine,
Division of Angiology, University Hospita4 Inselspital, Freiburgstrasse, CH-
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